3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Glioblastoma
5
Gliosarcoma
4
Squamous Cell Carcinoma of Head and Neck
3
Glioma
3
Brain Neoplasms
3
Treatment-Refractory Solid Tumors
2
Salivary Gland Neoplasms
2
Central Nervous System Neoplasms
2
Tongue Neoplasms
1
Oligodendroglioma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
HPV-Negative Squamous Cell Carcinoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Carcinoma, Non-Small-Cell Lung
1
Bites and Stings
1
Astrocytoma
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
3
blinatumomab
2
enzalutamide
1
durvalumab
1
dostarlimab
1
cemiplimab
1
atezolizumab
1
abiraterone
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Immune Checkpoint Inhibitors
1
Hydroxyurea
1
Etoposide
1
Etanercept
1
Cytochrome P-450 Enzyme System
1
Carboplatin
1
AMG 757
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Bites and Stings
×
Hydroxyurea
×
Clear all
NCT06063317
2026-03-06
OASIS
Imugene Limited
Phase 1
Terminated
25 enrolled